Secondary analysis of a phase II trial of preoperative radiotherapy with or without pembrolizumab in 106 patients with localised soft tissue sarcoma: personalised ctDNA was found in 85% at baseline and levels independently predicted survival.
Secondary analysisn = 106
Subramanian et al. Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial